Trial Profile
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 13 Dec 2022 Results assessing the spatial-temporal interactions between T cells and leukemia cells in R-AML during treatment with ICB and HMA at single-cell resolution.presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 03 Apr 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology